Jasper Therapeutics, Inc. (JSPR) stock
JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$13.37−1.39 (-9.42%)
Close on Nov 12, 2026Market cap $444.88MP/E –Yield –
Jasper Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Jasper Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$54.60M. For fiscal 2025 it was -$82.83M. The highest annual figure on record is -$36.46M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$82.83M | – |
| FY2024 | Dec 31, 2024 | -$74.87M | – |
| FY2023 | Dec 31, 2023 | -$67.75M | – |
| FY2022 | Dec 31, 2022 | -$50.22M | – |
| FY2021 | Dec 31, 2021 | -$36.46M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.19M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.55M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.94M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.82M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.52M | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.04M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.69M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.78M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.53M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.67M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.47M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.41M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.75M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.56M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.89M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.39M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.23M | – |
See a number that looks wrong?